Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.
作者信息
Sanderson Ralph D, Elkin Michael, Rapraeger Alan C, Ilan Neta, Vlodavsky Israel
机构信息
Department of Pathology, Comprehensive Cancer Center, University of Alabama at Birmingham, AL, USA.
Sharett Oncology Institute, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
出版信息
FEBS J. 2017 Jan;284(1):42-55. doi: 10.1111/febs.13932. Epub 2016 Nov 16.
Because of its impact on multiple biological pathways, heparanase has emerged as a major regulator of cancer, inflammation and other disease processes. Heparanase accomplishes this by degrading heparan sulfate which regulates the abundance and location of heparin-binding growth factors thereby influencing multiple signaling pathways that control gene expression, syndecan shedding and cell behavior. In addition, heparanase can act via nonenzymatic mechanisms that directly activate signaling at the cell surface. Clinical trials testing heparanase inhibitors as anticancer therapeutics are showing early signs of efficacy in patients further emphasizing the biological importance of this enzyme. This review focuses on recent developments in the field of heparanase regulation of cancer and inflammation, including the impact of heparanase on exosomes and autophagy, and novel mechanisms whereby heparanase regulates tumor metastasis, angiogenesis and chemoresistance. In addition, the ongoing development of heparanase inhibitors and their potential for treating cancer and inflammation are discussed.